Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85175 | 0.94 | ALDH1A1 (0.58) | ALDH1A1HPGDAKR1C3DDB1CRBN | |
| SCHEMBL85591 | 0.92 | ALDH1A1 (0.57) | ALDH1A1HPGDAKR1C3DDB1CRBN | |
| SCHEMBL11142367 | 0.91 | ALDH1A1 (0.74) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 | |
| SCHEMBL11936018 | 0.82 | USP2 (0.52) | ALDH1A1HPGDSMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL1656668 | 0.82 | ALDH1A1 (0.68) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 | |
| SCHEMBL1171241 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 | |
| SCHEMBL19356857 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 | |
| SCHEMBL624432 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 | |
| SCHEMBL1507158 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 | |
| SCHEMBL171739 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HPGDAKR1C3SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117721634-A | Amphiphilic functionalized graphene fiber and preparation method thereof | 兰州东立龙信息技术有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-112976746-B | Polyester film for antistatic dry film resist and preparation method thereof | 富维薄膜（山东）有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-116096194-A | Novel method for preparing large-area perovskite film and application | 合肥市旭熠科技有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-112976746-A | Polyester film for antistatic dry film resist and preparation method thereof | 富维薄膜（山东）有限公司 | 2021-06-18 | — | — | CN | claimed |
| CN-108587111-B | Composite efficient antistatic agent for plastics | 湖南辰砾新材料有限公司 | 2021-04-30 | — | — | CN | claimed |
| CN-111892806-A | Preparation method of composite efficient antistatic agent for plastics | 湖南辰砾新材料有限公司 | 2020-11-06 | — | — | CN | claimed |
| CN-108587111-A | Composite efficient antistatic agent for plastics | 湖南辰砾新材料有限公司 | 2018-09-28 | — | — | CN | claimed |
| EP-1628972-B1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-22 | — | — | EP | claimed |
| US-7365088-B2 | Indazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-29 | — | — | US | claimed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | claimed |
| EP-1628972-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-01 | — | — | EP | claimed |
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | US | claimed |
| WO-2004101556-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| EP-1479675-A1 | Indazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| US-20260125357-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | GLIAPHARM SA (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4598533-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | Gliapharm SA (CH) | 2025-08-13 | — | — | EP | disclosed |
| CN-120035439-A | Lactic acid enhancing compounds and uses thereof | 格莱制药股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-1997038095-A1 | COMPLEX SUPEROXIDE DISMUTASE PRODUCT | COLETICA (FR) | 1997-10-16 | — | — | WO | disclosed |
| US-4211835-A | TETRAZOLIUM COMPOUND, BLACK AND WHITE, HIGH CONTRAST | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1980-07-08 | — | — | US | disclosed |
| US-3980677-A | Anthraquinone dyestuffs containing sulphonic acid groups | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125357-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | LDHA, PC, LDHB | ALDH1A1 405/4885HPGD 498/4885AKR1C3 78/4885 |
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | F11, F12, F5 | ALDH1A1 1259/4885HPGD 678/4885AKR1C3 887/4885 |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | ALDH1A1 4215/4885HPGD 1261/4885AKR1C3 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.